MAY 29, 2020 8:48 AM PDT

What can we do about drug-induced tetraploidy in cancer cells?

A paper published in the journal Trends in Cancer describes how cancer therapies sometimes fuel genetic changes in cells that lead to resistance. During this process, rogue cells grow in size, significantly expanding the number of chromosomes the cell should have. This phenomenon is of obvious concern to oncologists. Daruka Mahadevan, MD, PhD, has spent the last 20 years investigating this, and reports on a potential method for deterring it with co-author Gregory C. Rogers, Ph.D. Mahadevan is a professor and chief of the Division of Hematology-Oncology in the Long School of Medicine at UT Health San Antonio. 

"When you give therapy, some cells don't die," explained Dr. Mahadevan. "These cells don't die because they've acquired a double complement of the normal chromosomes plus other genetic changes. Many types of chemotherapy actually promote this."

Photo: Pixabay

The paper explains that these cells can have up to 8, 16, or even 32 times the number of chromosomes found in healthy cells. The authors say that two specific genes, c-Myc and BCL2, drive the genetic changes in the tetraploid cells. c-Myc and BCL2 are known to play a role in "double-hit" high-grade lymphomas, which are incurable.

"These genes are part of the problem because when they are present, they help the lymphoma cells to live longer and prime them to become large cells with treatment," said Mahadevan."It's a double hit, a double whammy."

These tetraploid cells will eventually result in cancer recurrence. As the authors write, “Drug-induced tetraploidy (DIT) in cancer cells is not only a mechanism of inherited drug resistance; proliferating DIT cells can produce progeny with increased ploidy or aneuploid genomes that drive aggressive disease.”

In response to this phenomenon, Mahadevan and Rogers have identified a small-molecule inhibitor that could prevent or treat DIT in cancer cells. The idea is that such a drug, once developed, could be used in concordance with chemotherapies to prevent large cell resistance.

Sources: Trends in Cancer, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
SEP 16, 2020
Cancer
Does Discontinuation of Immunotherapy Effect Final Results in Metastatic Melanoma?
SEP 16, 2020
Does Discontinuation of Immunotherapy Effect Final Results in Metastatic Melanoma?
The last decade has seen the emergence of several new therapies against cancer. For melanoma, checkpoint inhibitors have ...
SEP 14, 2020
Cancer
We are too uneducated on the risks of colon cancer
SEP 14, 2020
We are too uneducated on the risks of colon cancer
A study conducted by researchers from Florida Atlantic University's Schmidt College of Medicine suggests that too ma ...
OCT 14, 2020
Cancer
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
OCT 14, 2020
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
Cold atmospheric plasma is a relatively new technique that utilizes a tool that generates a sort of plasma scalpel, exce ...
OCT 18, 2020
Cancer
Virus-mimicking drug attacks melanoma tumors
OCT 18, 2020
Virus-mimicking drug attacks melanoma tumors
Research published recently in the journal Science Translational Medicine from scientists at the UCLA Jonsson Compr ...
NOV 18, 2020
Cancer
Could Targeting the Proteasome be Effective Against Cancer?
NOV 18, 2020
Could Targeting the Proteasome be Effective Against Cancer?
One of the trickiest things about anti-cancer drug design is targeting. Today, most drugs on the market target critical ...
NOV 27, 2020
Cell & Molecular Biology
UVC Rays May be a Bigger Cancer Risk Than Known
NOV 27, 2020
UVC Rays May be a Bigger Cancer Risk Than Known
The sun emits different kinds of light and rays including visible and ultraviolet (UV) and infrared. Some of those forms ...
Loading Comments...